Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CSL ( (AU:CSL) ) has issued an announcement.
CSL Limited announced the cessation of 410 securities due to the lapse of conditional rights, as the conditions required for these rights were not met or became incapable of being satisfied. This announcement may impact CSL’s issued capital and reflects the company’s ongoing management of its securities and financial operations.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative medicines and therapies. The company is known for its work in plasma-derived therapies, vaccines, and recombinant proteins, serving a global market with a strong emphasis on healthcare solutions.
Average Trading Volume: 1,351,815
Technical Sentiment Signal: Sell
Current Market Cap: A$85.87B
See more insights into CSL stock on TipRanks’ Stock Analysis page.